Cristo Chaskis

Cristo Chaskis

Auto-generated profile, based on publicly available information

Cristo Chaskis

Department of Neurosurgery, Academic Hospital, Vrije Universiteit Brussel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
BNBart Neyns
Bart Neyns
JSJ. Sadones
J. Sadones
EJE. Joosens
E. Joosens
FBF. Bouttens
F. Bouttens
LVL. Verbeke
L. Verbeke
JGJ. De Greve
J. De Greve
Background: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and chemotherapy. Patients and methods: In this two-arm, open-label, phase II study patients were stratified according to their epidermal growth factor receptor (EGFR) gene amplification status. Cetuximab was administered intravenously at a dose of 400 mg/m2 on week 1 followed by weekly dose of 250 mg/m2. The primary end point for this study was the response rate in both study arms separately. Results: Fifty-five eligible patients (28 with and 27 without EGFR amplification) tolerated cetuximab well. Three patients (5.5%) had a partial response and 16 patients (29.6%) had stable disease. The median time to progression was 1.9 months [95% confidence interval (CI) 1.6–2.2 months]. Whereas the progression-free survival (PFS) was 9 months. Median overall survival was 5.0 months (95% CI 4.2–5.9 months). No significant correlation was found between response, survival and EGFR amplification. Conclusions: Cetuximab was well tolerated but had limited activity in this patient population with progressive HGG. A minority of patients may derive a more durable benefit but were not prospectively identified by EGFR gene copy number.

1 October 2009 in Surgical Neurology
Verified
Journal Article
Closed access
CCCristo Chaskis
Cristo Chaskis
BNBart Neyns
Bart Neyns
AMAlex Michotte
Alex Michotte
Mark De RidderMark De Ridder
Mark De Ridder
HEHendrik Everaert
Hendrik Everaert

25 September 2010 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BNBart Neyns
Bart Neyns
JSJ. Sadones
J. Sadones
CCC. Chaskis
C. Chaskis
MDM. Dujardin
M. Dujardin
HEH. Everaert
H. Everaert
JGJ. De Greve
J. De Greve

1 May 2001
Verified
Journal Article
Closed access
TSTadeusz W. Stadnik
Tadeusz W. Stadnik
CCCristo Chaskis
Cristo Chaskis
AMAlex Michotte
Alex Michotte
WSWael M. Shabana
Wael M. Shabana
KRKatrijn van Rompaey
Katrijn van Rompaey
MOMichel Osteaux
Michel Osteaux

19 January 2006 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
CCC. Chaskis
C. Chaskis
TST. Stadnik
T. Stadnik
AMA. Michotte
A. Michotte
KRK. Van Rompaey
K. Van Rompaey
JDJ. D’hAens
J. D’hAens

1 January 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
JSJ. Sadones
J. Sadones
AMA. Michotte
A. Michotte
PVP. Veld
P. Veld
CCC. Chaskis
C. Chaskis
RSR. Sciot
R. Sciot
BNBart Neyns
Bart Neyns